Lithotripsy Devices Market Size & Growth Forecast 2026–2035, By Segments (Type, End-use, Application), Regional Demand Trends (North America, Asia Pacific, Europe), Key Country Insights (U.S., Japan, South Korea, Germany, France, Italy), and Competitive Landscape

Market Size and Growth Outlook

Lithotripsy Devices Market size was over USD 1.41 Billion in 2025 and is likely to grow at a 6.5% CAGR between 2026 and 2035, attaining USD 2.65 Billion by 2035. The industry revenue for 2026 is assessed at USD 1.49 billion.

• Base Year Value (2025): USD 1.41 Billion
• CAGR (2026-2035): 6.5%
• Forecast Year Value (2035): USD 2.65 Billion
• Historical Data Period: 2022-2025
• Largest Region: North America
• Forecast Period: 2026-2035

Lithotripsy Devices Market Intelligence Snapshot:

• Regional Market Dynamics:

  • North America leads the market through established hospital networks, high urology procedure volumes, advanced technology adoption, and steady demand for equipment upgrades across care settings.
  • Asia Pacific is projected to grow at a 7.35% CAGR, supported by expanding hospital infrastructure, broader access to urology care, and increasing adoption of modern minimally invasive stone treatment procedures.

• Segment Momentum:

  • Extracorporeal Shock Wave Lithotripsy Devices captured a 53.55% share in 2025 because their non-invasive approach supports efficient treatment, broad clinical adoption, and high patient throughput across healthcare settings.
  • Ambulatory Surgical Centers are the fastest-growing end-use segment as more lithotripsy procedures shift toward efficient outpatient care with streamlined scheduling, shorter stays, and focused procedural delivery.

• Market Expansion Drivers:

  • Rising kidney stone prevalence increasing demand for minimally invasive lithotripsy procedures.
  • Technological advancements improving precision and safety of next-generation lithotripsy devices.
  • Expansion of ambulatory surgical centers supporting outpatient lithotripsy treatment adoption.

• Leading Market Participants:

  Prominent companies in the lithotripsy devices market include Boston Scientific Corporation (United States), Olympus Corporation (Japan), Dornier MedTech GmbH (Germany), Richard Wolf GmbH (Germany), STORZ MEDICAL AG (Switzerland), Medispec Ltd. (Israel), BTL Industries Inc. (United States), Zimmer MedizinSysteme GmbH (Germany), Shenzhen Huikang Medical Apparatus Co., Ltd. (China), MTS Medical UG (Germany).

Unlock Complete Insights

Global Market Forecast Snapshot:

• Market Outlook:

  • 2025 Market Size: USD 1.41 Billion
  • Projected Market Size: USD 2.65 Billion by 2035
  • Growth Forecasts: 6.5% CAGR (2026-2035)

• Regional and Segment Outlook:

  • Leading Regional Market: North America
  • High-Growth Regional Hub: Asia Pacific
  • Core Revenue Segment: Extracorporeal Shock Wave Lithotripsy Devices (Type) | Hospitals (End-use) | Kidney Stones (Application)
  • Emerging Opportunity Segment: Intracorporeal Lithotripsy Devices (Type) | Ambulatory Surgical Centers (End-use) | Pancreatic Stones (Application)

Market Growth Drivers and Industry Trends

Rising kidney stone prevalence increasing demand for minimally invasive lithotripsy procedures

As kidney stone incidence rises across broader patient groups, providers are seeing a larger procedural pool that increasingly favors non-invasive or minimally invasive treatment pathways over open surgery. This is driving demand for the lithotripsy devices market because urologists and hospitals need equipment that can fragment stones effectively while reducing hospital stays, post-procedure pain, and recovery time. In practice, higher case volumes push treatment centers to expand access to extracorporeal shock wave lithotripsy and advanced intracorporeal systems, reinforcing purchasing decisions around versatile devices that can manage different stone sizes and locations without adding significant surgical burden.

Technological advancements improving precision and safety of next-generation lithotripsy devices

Innovation in imaging guidance, energy delivery, stone targeting, and fragmentation control is reshaping clinician preferences in the lithotripsy devices market by improving procedural accuracy and reducing collateral tissue injury. Hospitals and specialists are more willing to upgrade installed systems when newer platforms support better visualization, more consistent stone clearance, and fewer repeat interventions, since these factors directly affect workflow efficiency and clinical confidence. This is influencing market adoption most strongly in settings where device performance, patient safety, and treatment predictability determine capital allocation and physician choice.

Expansion of ambulatory surgical centers supporting outpatient lithotripsy treatment adoption

The growth of ambulatory surgical centers is changing where stone management is delivered, creating a strong commercial channel for compact, efficient, and procedure-friendly systems in the lithotripsy devices market. As more lithotripsy cases shift to outpatient settings, providers prioritize devices that fit shorter treatment cycles, streamlined staffing models, and faster patient turnover without compromising treatment effectiveness. That shift is aiding market expansion by broadening the base of purchasing facilities beyond large hospitals and encouraging manufacturers to align product design, service models, and training support with the operational needs of ambulatory care.

Growth Driver Assessment Framework
Growth Driver	Impact On CAGR	Regulatory Influence	Geographic Relevance	Adoption Rate	Impact Timeline
Increasing prevalence of kidney stones and urological conditions	2.10%	Short term (≤ 2 yrs)	North America, Europe	Medium	Fast
Expansion of minimally invasive lithotripsy procedures	2.20%	Medium term (2–5 yrs)	Europe, Asia Pacific	Medium	Moderate
Innovation in lithotripsy device design and efficiency	2.20%	Long term (5+ yrs)	North America, Asia Pacific	Medium	Moderate
Rising kidney stone prevalence increasing demand for minimally invasive lithotripsy procedures	2.00%	Moderate	North America, Asia Pacific	High	Near Term
Technological advancements improving precision and safety of next-generation lithotripsy devices	1.80%	Moderate	Europe, North America	High	Mid Term
Expansion of ambulatory surgical centers supporting outpatient lithotripsy treatment adoption	1.50%	Moderate	North America, Europe	Emerging	Mid Term

Regional Demand Dynamics

North America (Largest Region) vs Asia Pacific (Fastest-Growing Region)

North America held the largest regional market share in 2025 for the lithotripsy devices market, bolstered by broad access to established hospital networks, higher procedural volumes for urology care, and faster integration of advanced stone management technologies into routine clinical practice. The region’s leadership is strengthened by the presence of well-equipped treatment centers that can adopt extracorporeal and minimally invasive lithotripsy systems efficiently, alongside physician familiarity with device-based stone fragmentation procedures. This operating environment keeps utilization steady across inpatient and outpatient settings, helping sustain demand for replacement systems, technology upgrades, and procedure-support equipment.

Asia Pacific is projected to expand at a 7.35% CAGR over the forecast period, with growth in the lithotripsy devices market being propelled by rising access to urological treatment, expanding hospital infrastructure, and wider adoption of modern stone treatment procedures across developing healthcare systems. As more facilities invest in specialized equipment and patients gain greater access to diagnosis and intervention, demand is accelerating for lithotripsy platforms that can support less invasive treatment pathways. The region’s momentum is also shaped by the practical shift from limited conventional management toward device-enabled procedures in urban and emerging care centers.

Regional Market Attractiveness & Strategic Fit Matrix
Parameter	North America	Asia Pacific	Europe	Latin America	MEA
Innovation Hub	Advanced	Developing	Advanced	Developing	Developing
Cost-Sensitive Region	Low	High	Medium	High	High
Regulatory Environment	Supportive	Neutral	Supportive	Neutral	Neutral
Demand Drivers	Strong	Strong	Strong	Moderate	Moderate
Development Stage	Developed	Developing	Developed	Developing	Emerging
Adoption Rate	High	High	High	Medium	Medium
New Entrants / Startups	Moderate	Moderate	Moderate	Sparse	Sparse
Macro Indicators	Strong	Strong	Stable	Stable	Stable

Key Country Insights

United States

Minimally Invasive Care

The U.S. lithotripsy devices market is driven by growing preference for minimally invasive kidney stone treatment and continual hospital technology upgrades. Healthcare providers are adopting advanced systems that improve treatment precision, workflow efficiency, and patient recovery.

Japan

Compact Treatment Technologies

Japan is advancing lithotripsy device adoption through compact, high-performance systems suited to technologically advanced healthcare facilities. Clinical priorities include patient comfort, procedural efficiency, and consistent treatment outcomes.

South Korea

Hospital Technology Upgrades

South Korea continues modernizing urology departments with lithotripsy devices that enhance precision and operational efficiency. Healthcare providers are investing in integrated treatment platforms supporting streamlined diagnosis and intervention.

Germany

Precision Urology Systems

Germany emphasizes lithotripsy devices offering reliable performance and integration with advanced urology practices. Medical equipment manufacturers continue refining imaging capabilities and treatment accuracy to support specialized clinical procedures.

France

Clinical Workflow Optimization

France is strengthening lithotripsy device utilization by improving access to minimally invasive stone management in hospitals. Procurement decisions increasingly favor systems offering dependable imaging integration and efficient clinical workflows.

Italy

Specialized Urology Expansion

Italy is expanding lithotripsy device deployment across specialized urology centers seeking effective non-invasive treatment options. Equipment suppliers are focusing on user-friendly systems that support consistent procedural performance and patient care quality.

Segment Leadership and Growth Trends

  Type Segment Analysis: Extracorporeal Shock Wave Lithotripsy Devices (Largest Segment) vs Intracorporeal Lithotripsy Devices (Fastest-Growing Segment)

Extracorporeal Shock Wave Lithotripsy Devices held the leading position in the lithotripsy devices market in 2025, accounting for a 53.55% share. This leadership is underpinned by their established role in non-invasive stone treatment, which supports broad adoption across care settings that prioritize procedural efficiency and patient throughput. Their continued use reflects routine clinical familiarity and the practical advantage of treating appropriate cases without the need for more invasive access, helping this segment preserve its dominant share in the lithotripsy devices market.

Intracorporeal Lithotripsy Devices are emerging as the fastest-growing segment in the lithotripsy devices market as treatment approaches increasingly align with procedures that require direct stone access and targeted fragmentation. Growth is being aided by the practical need for greater procedural precision in cases where non-invasive methods may be less suitable, giving intracorporeal systems stronger momentum relative to alternatives. As clinical settings continue to adopt intervention pathways designed around more controlled stone management, this segment is experiencing stronger uptake at a faster pace.

End-use Segment Analysis: Hospitals (Largest Segment) vs Ambulatory Surgical Centers (Fastest-Growing Segment)

Hospitals represented the largest end-use segment of the lithotripsy devices market in 2025, with a 48.44% share. Their leadership is anchored in the ability to manage a broad range of stone cases, including patients requiring integrated diagnostics, specialist support, and access to more comprehensive procedural infrastructure. This concentration of treatment capabilities allows hospitals to retain the largest share in the lithotripsy devices market, especially where case complexity and peri-procedural management remain important considerations.

Ambulatory Surgical Centers are the fastest-growing end-use segment in the lithotripsy devices market, driven by the rising suitability of selected lithotripsy procedures for efficient outpatient care. Their momentum comes from operating models built around shorter stays, streamlined scheduling, and focused procedural delivery, which make them increasingly attractive for cases that do not require full hospital resources. Compared with traditional inpatient-oriented settings, ambulatory surgical centers are gaining faster adoption as providers respond to demand for more efficient treatment pathways.

Report Segmentation
Segment	Sub-Segment	Largest Segment	Fastest Growing Segment
Type	Extracorporeal Shock Wave Lithotripsy Devices, Intracorporeal Lithotripsy Devices	Extracorporeal Shock Wave Lithotripsy Devices	Intracorporeal Lithotripsy Devices
End-use	Hospitals, Ambulatory Surgical Centers, Others	Hospitals	Ambulatory Surgical Centers
Application	Kidney Stones, Ureteral Stones, Pancreatic Stones, Bile Duct Stones	Kidney Stones	Pancreatic Stones

Competitive Landscape and Market Positioning

Prominent players in the lithotripsy devices market:

1. Boston Scientific Corporation (United States)

2. Olympus Corporation (Japan)

3. Dornier MedTech GmbH (Germany)

4. Richard Wolf GmbH (Germany)

5. STORZ MEDICAL AG (Switzerland)

6. Medispec Ltd. (Israel)

7. BTL Industries Inc. (United States)

8. Zimmer MedizinSysteme GmbH (Germany)

9. Shenzhen Huikang Medical Apparatus Co. Ltd. (China)

10. MTS Medical UG (Germany)

Minimally invasive treatment demand is driving innovation in the lithotripsy devices market. In the lithotripsy devices market, precision energy delivery systems and improved procedural control are enhancing treatment efficiency and patient recovery.

Competitive Dynamics and Strategic Insights
Assessment Parameter	Assigned Scale	Scale Justification
Market Concentration	Medium	The market has several key players, but no single OEM dominates, indicating a balanced competitive landscape.
M&A Activity / Consolidation Trend	Moderate	There have been some strategic acquisitions aimed at enhancing product portfolios, but overall activity remains moderate.
Degree of Product Differentiation	High	Innovative technologies and varying treatment modalities contribute to significant product differentiation among manufacturers.
Competitive Advantage Sustainability	Durable	Established brands with strong R&D capabilities maintain a durable competitive advantage through continuous innovation.
Innovation Intensity	High	Rapid advancements in technology, including laser and ultrasound lithotripsy, drive high levels of innovation in the market.
Customer Loyalty / Stickiness	Moderate	While some hospitals and clinics show brand loyalty, the availability of alternative technologies can lead to moderate stickiness.
Vertical Integration Level	Low	Most manufacturers focus on specific segments of the lithotripsy device supply chain rather than pursuing vertical integration.

Industry Development/News

Company Name	Date	Key Development
Boston Scientific Corporation	Mar-21	Boston Scientific acquired Lumenis, expanding its presence in lithotripsy and minimally invasive urology treatment solutions. The acquisition strengthens its portfolio in energy-based medical devices and supports broader adoption of advanced stone treatment technologies across global healthcare markets.
Dornier MedTech	Mar-21	Dornier MedTech achieved EU MDR certification for its Class IIb lithotripsy systems, including the Delta III lithotripter and UIMS platform. The certification enhances regulatory compliance and strengthens its competitive positioning in the European medical device market for extracorporeal shock wave lithotripsy systems.
Avvio Medical	May-25	Avvio Medical reported first patient treatments using its investigational Enhanced Lithotripsy System following FDA IDE approval. The milestone advances clinical validation of next-generation lithotripsy technology designed to improve kidney stone fragmentation and minimally invasive treatment outcomes.
SonoMotion	Nov-24	SonoMotion received FDA de-novo clearance for its Stone Clear device, an ultrasound-based platform designed to mobilize residual stone fragments post-lithotripsy. The approval expands post-procedure treatment capabilities and enhances non-invasive stone management workflows.
Shvabe Holding	Dec-24	Shvabe Holding unveiled a certified extracorporeal shock-wave lithotripter aimed at replacing imported systems in Russian clinical settings. The development supports domestic medical device production and expands access to lithotripsy technologies in local healthcare infrastructure.